TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - AMGEN TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - AMGEN Share Price
Certificat
DE000SF7VWH2
| Market Closed - Deutsche Boerse AG 20:51:01 25/06/2024 BST | ||
| 13.49 EUR | +2.74% |
|
| Current month | +12.04% | ||
| 1 month | +10.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 13.49 | +2.74% |
| 24/06/24 | 13.13 | +3.79% |
| 21/06/24 | 12.65 | +1.04% |
| 20/06/24 | 12.52 | +3.39% |
| 19/06/24 | 12.11 | -0.33% |
Delayed Quote Deutsche Boerse AG
Last update June 25, 2024 at 08:51 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Société Générale
|
| WKN | SF7VWH |
| ISIN | DE000SF7VWH2 |
| Date issued | 23/08/2021 |
| Strike | 177.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.26 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.41 € |
|---|---|
| Lowest since issue | 4.14 € |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
319.3
USD
Average target price
316.4
USD
Spread / Average Target
-0.90%
- Stock Market
- Certificates
- Certificat
